QuidelOrtho Corporation (QDEL)
Nasdaq: QDEL · In Vitro & In Vivo Diagnostic Substances · San Diego, CA · filing with the SEC since 2022
Grade4.8
◀ Past 5.8● Present 5.0▶ Future 3.6
Filings
159 filings since 2017 beside 343 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Jan 1, 2027Large accelerated filers have 60 days after the fiscal year ends.
by Mar 2, 2027
10-Q
Quarterly report for the quarter ending Apr 30, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by Jun 9, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 37 days after the quarter ended. The proxy statement was last filed Apr 27, 2026.
Filings a yearinsider forms included
83871469195
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 15 times in the last 36 months, the newest Nov 3, 2026.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Mar 4, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 3, 2026
8-K items 2.02, 5.02, 9.01
Results released; Officer or director change · Current report
Jun 23, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Jun 22, 2026
Mar 24, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Mar 18, 2026
40 of 159 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.